MARKET

THRX

THRX

Theseus Pharmaceuticals, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.65
+0.87
+11.18%
Opening 09:52 08/18 EDT
OPEN
7.90
PREV CLOSE
7.78
HIGH
8.65
LOW
7.90
VOLUME
1.82K
TURNOVER
10.73K
52 WEEK HIGH
24.54
52 WEEK LOW
4.857
MARKET CAP
334.87M
P/E (TTM)
-8.8337
1D
5D
1M
3M
1Y
5Y
Theseus Pharmaceuticals GAAP EPS of -$0.30 in-line
Theseus Pharmaceuticals press release (<span...
Seekingalpha · 08/11 13:29
BRIEF-Theseus Pharmaceuticals reports Q2 results
BRIEF-Theseus Pharmaceuticals reports Q2 results
Reuters · 08/11 11:07
Theseus Pharmaceuticals to Participate Virtually in Wedbush PacGrow Healthcare Conference
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapie...
PR Newswire · 08/03 12:30
HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock
Benzinga · 07/01 16:48
Theseus Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein initiated coverage of Theseus Pharmaceuticals (THRX) with a Buy ...
Seekingalpha · 06/30 19:01
HC Wainwright Initiates Coverage on Theseus Pharmaceuticals With Buy Rating, $22 Price Target
MT Newswires · 06/30 09:31
Companies Like Theseus Pharmaceuticals (NASDAQ:THRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Simply Wall St. · 06/16 10:22
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 84 companies set new 52-week lows.
Benzinga · 06/09 17:21
More
No Data
Learn about the latest financial forecast of THRX. Analyze the recent business situations of Theseus Pharmaceuticals, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
40.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average THRX stock price target is 21.60 with a high estimate of 24.00 and a low estimate of 18.00.
High24.00
Average21.60
Low18.00
Current 8.65
EPS
Actual
Estimate
-4.13-3.10-2.06-1.03
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 47
Institutional Holdings: 34.95M
% Owned: 90.31%
Shares Outstanding: 38.71M
TypeInstitutionsShares
Increased
13
560.38K
New
4
69.47K
Decreased
15
443.13K
Sold Out
4
63.48K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.44%
Pharmaceuticals & Medical Research
-0.51%
Key Executives
Chairman/Co-Founder/Executive Director
Iain Dukes
President/Chief Executive Officer/Director/Primary Contact
Timothy Clackson
Co-Founder/Chief Technology Officer
David Dalgarno
Co-Founder/Chief Scientific Officer
Victor Rivera
Chief Financial Officer
Bradford Dahms
Corporate Executive
William Shakespeare
Executive Officer
David Kerstein
Director
Carl Gordon
Independent Director
Donald Hayden
Independent Director
Michael Rome
Independent Director
Kathy Yi
No Data
No Data
About THRX
Theseus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on treating cancer patients through the discovery, development and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in oncogenes, which are mutated genes that cause cancer. The Company is focused on developing tyrosine kinase inhibitors (TKI), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It is focused to development of pan-variant kinase inhibitors that target all cancer causing and drug resistance mutations in clinically protein kinases. The Company's product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase, or a pan-KIT inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT.

Webull offers kinds of Theseus Pharmaceuticals Inc stock information, including NASDAQ:THRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, THRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading THRX stock methods without spending real money on the virtual paper trading platform.